| Literature DB >> 32053640 |
Abdullah H Baqui1, Eric D McCollum1,2, Arif Mahmud3, Arunangshu Roy3, Nabidul H Chowdhury3, Iftekhar Rafiqullah4, Syed Jafar Raza Rizvi3, Nazma Begum3, Dipak K Mitra4, Rasheda Khanam1, Meagan Harrison1, Salahuddin Ahmed3, Md Hasanuzzaman5, Hafizur Rahman5, Maksuda Islam5, Zabed B Ahmed5, Md Abdul Quaiyum6, Alain Koffi1, Nicole Simmons1, William Checkley1,7, Lawrence H Moulton1, Mathuram Santosham1, Samir K Saha5.
Abstract
BACKGROUND: Bangladesh introduced the 10-valent pneumococcal conjugate vaccine (PCV-10) in 2015. We measured population-based incidence of invasive pneumococcal disease (IPD) prior to introduction of PCV-10 to provide a benchmark against which the impact of PCV-10 can be assessed.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32053640 PMCID: PMC7018078 DOI: 10.1371/journal.pone.0228799
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Study flow chart, January 2014—June 2015.
Weekly prevalence of suspected pneumonia, meningitis and isolated fever based on two-monthly home visit surveillance, stratified by age, January 2014-June 2015, Sylhet, Bangladesh.
| Age in months | Number of children who were present during visit (N) | Number of suspected Pneumonia cases N (%) | Number of suspected Meningitis cases | Number of isolated fever Cases | Number of suspected IPD cases |
|---|---|---|---|---|---|
| 0–2 | 19,608 | 399 (2.0) | 11 (0.06) | 1,911 (9.7) | 2,321 (11.8) |
| 3–5 | 23,074 | 810 (3.5) | 7 (0.03) | 3,349 (14.5) | 4,166 (18.1) |
| 6–11 | 48,353 | 1,582 (3.3) | 35 (0.07) | 7,781 (16.1) | 9,398 (19.4) |
| 12–23 | 104,995 | 2,557 (2.4) | 78 (0.07) | 14,646 (13.9) | 17,281 (16.5) |
| 24–35 | 108,152 | 2,059 (1.9) | 45 (0.04) | 13,103 (12.1) | 15,207 (14.1) |
| 36–47 | 101,332 | 1,409 (1.4) | 27 (0.03) | 10,736 (10.6) | 12,172 (12) |
| 48–59 | 94,232 | 1,034 (1.1) | 24 (0.03) | 8,774 (9.3) | 9,832 (10.4) |
| Total | 499,746 | 9,850 (2.0) | 227 (0.05) | 60,300 (12.1) | 70,377 (14.1) |
Care-seeking by reported morbidity categories based on two-monthly home visit surveillance, January 2014-June 2015, Sylhet, Bangladesh.
| Place of care | Suspected Pneumonia (%) | Suspected Meningitis (%) | Isolated Fever (%) | Suspected IPD (%) |
|---|---|---|---|---|
| No Care | 2,376 (24.1) | 37 (16.3) | 19,212 (31.9) | 21,625 (30.7) |
| Home | 142 (1.4) | 5 (2.2) | 1,759 (2.9) | 1,906 (2.7) |
| Pharmacy/ Village doctor | 4,008 (40.7) | 63 (27.8) | 25,872 (42.9) | 29,943 (42.6) |
| 1,216 (12.4) | 43 (18.9) | 4,131 (6.9) | 5,390 (7.7) | |
| Medical College Hospital | 56 (0.6) | 7 (3.1) | 75 (0.1) | 138 (0.2) |
| Private (office, clinic, hospital) | 1,443 (14.7) | 62 (27.3) | 5,533 (9.2) | 7,038 (10) |
| Satellite/Community Clinic/FWC | 399 (4.1) | 3 (1.3) | 2,027 (3.4) | 2,429 (3.5) |
| Don't know/ Other | 210 (2.1) | 7 (3.1) | 1,691 (2.8) | 1,908 (2.7) |
| Total | 9,850 | 227 | 60,300 | 70,377 |
Age-specific number of hospital visits, eligible cases and blood and CSF specimen collected among children 0–59 months of age, January 2014-June 2015, Sylhet, Bangladesh.
| Age in months | Screened | Blood culture | CSF culture | ||||
|---|---|---|---|---|---|---|---|
| Clinically eligible | Enrollable | Blood collected | Clinically eligible | Enrollable | CSF collected | ||
| 0–2 | 5,814 | 1,189 | 903 | 727 (80.5%) | 113 | 111 | 6 (5.4%) |
| 3–5 | 6,437 | 1,585 | 1,193 | 944 (79.1%) | 123 | 122 | 10 (8.2%) |
| 6–11 | 11,580 | 2,829 | 2,139 | 1,680 (78.5%) | 241 | 241 | 37 (15.4%) |
| 12–23 | 16,299 | 3,730 | 2,872 | 2,302 (80.2%) | 349 | 349 | 53 (15.2%) |
| 24–35 | 11,743 | 2,492 | 2,014 | 1,672 (83.0%) | 193 | 193 | 44 (22.8%) |
| 36–47 | 7,083 | 1,289 | 1,037 | 865 (83.4%) | 107 | 106 | 23 (21.7%) |
| 48–59 | 4,428 | 697 | 564 | 478 (84.8%) | 54 | 53 | 4 (7.6%) |
| Total | 63,384 | 13,811 | 10,722 | 8,668 (80.8%) | 1,180 | 1,175 | 177 (15.1%) |
a 3,089 cases were eligible but were excluded due to prior antibiotic use or enrollment as a potential IPD case in the preceding 7 days
b1,948 were enrollable but did not provide consent; 106 cases were enrolled but had no blood collected due to other reasons (attempt failure, not in condition to collect blood)
c 5 cases were eligible but were excluded due to enrollment as a potential IPD case in the preceding 7 days.
d 970 enrollable cases did not consent; CSF not collected from another 28 enrollable cases for other reasons (attempt failure, not in condition to collect CSF)
Fig 2Serotype distribution of pneumococcal isolates prior to introduction of PCV-10, Sylhet, Bangladesh.
Number of PCV-10 type and non-vaccine type Streptococcus pneumoniae isolated from blood and CSF samples by age among children 0–59 months of age, January 2014-June 2015, Sylhet, Bangladesh.
| Age (month) | Hospital visits | Blood cultures perform-ed | CSF cultures perform-ed | All IPD-positive culture results | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (n) | (n) | VT | NVT | NT | Total | (n) | VT | NVT | Total | VT | NVT | NT | Total | |
| 0–2 | 5,814 | 727 | 3 | 1 | 0 | 4 | 6 | 1 | 0 | 1 | 4 | 1 | 0 | 5 |
| 3–5 | 6,437 | 944 | 2 | 3 | 1 | 6 | 10 | 0 | 1 | 1 | 2 | 4 | 1 | 7 |
| 6–11 | 11,580 | 1,680 | 10 | 6 | 0 | 16 | 37 | 0 | 0 | 0 | 10 | 6 | 0 | 16 |
| 12–23 | 16,299 | 2,302 | 6 | 2 | 0 | 8 | 52 | 0 | 0 | 0 | 6 | 2 | 0 | 8 |
| 24–35 | 11,743 | 1,672 | 5 | 0 | 0 | 5 | 44 | 0 | 0 | 0 | 5 | 0 | 0 | 5 |
| 36–47 | 7,083 | 864 | 2 | 0 | 0 | 2 | 23 | 0 | 0 | 0 | 2 | 0 | 0 | 2 |
| 48–59 | 4,428 | 477 | 3 | 0 | 0 | 3 | 4 | 0 | 0 | 0 | 3 | 0 | 0 | 3 |
| 63,384 | 8,666 | 31 | 12 | 1 | 44 | 176 | 1 | 1 | 2 | 32 | 13 | 1 | 46 | |
* Includes non-typable/unknown
**There were two blood samples and 1 CSF sample with no report.
Age and sex-specific IPD case rate by year in active surveillance area per 100,000 child-years observed.
| Age in Month | Baseline (Jan 2014-Jun 2015) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Child year observed | # of IPD cases | IPD case rate per 100,000 child years | |||||||
| Male | Female | Total | Male | Female | Total | Male | Female | Total | |
| 0–2 Months | 3,263 | 3,210 | 6,472 | 5 | 0 | 5 | 153.2 (49.8–357.8) | 0.0 (0–0) | 77.3 (25.1–180.2) |
| 3–5 Months | 3,459 | 3,436 | 6,895 | 1 | 6 | 7 | 28.9 (0.7–161.1) | 174.6 (64.1–380.1) | 101.5 (40.8–209.2) |
| 6–11 Months | 6,491 | 6,360 | 12,851 | 9 | 7 | 16 | 138.7 (63.4–263.2) | 110.1 (44.3–226.8) | 124.5 (71.2–202.2) |
| 12–23 Months | 13,630 | 13,365 | 26,996 | 2 | 6 | 8 | 14.7 (1.8–53.0) | 44.9 (16.5–97.8) | 29.6 (12.8–58.4) |
| 24–35 Months | 13,690 | 13,269 | 26,960 | 4 | 1 | 5 | 29.2 (8.0–74.8) | 7.5 (0.2–42.0) | 18.6 (6.0–43.3) |
| 36–47 Months | 12,408 | 11,813 | 24,221 | 1 | 1 | 2 | 8.1 (0.2–45.0) | 8.5 (0.2–47.2) | 8.3 (1.0–29.8) |
| 48–59 Months | 11,480 | 10,782 | 22,262 | 3 | 0 | 3 | 26.1 (5.4–76.4) | 0.0 (0.0–34.2) | 13.5 (2.8–39.4) |
| Total | 64,422 | 62,235 | 126,657 | 25 | 21 | 46 | 38.8 (25.1–57.3) | 33.7 (20.9–51.6) | 36.3 (26.6–48.4) |
*95% confidence interval
Fig 3Serotype distribution and seasonality of pneumococcal isolates.